Edgewise Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
EWTX$46.53-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibit and Financial Statement Schedules
(a) The following documents are filed as part of this report:
(1) Financial Statements The financial statements of Edgewise Therapeutics, Inc. are filed as part of this report on Form 10-K under Item 8. Financial Statements and Supplementary Data.
(2) Financial Statement Schedules
All other schedules have been omitted because they are not required, are inapplicable, or the required information is included in the financial statements or notes thereto.
(3) Exhibits
The documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).
EXHIBIT INDEX
| | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Incorporated by Reference | ||||||||||
| ExhibitNumber · Exhibit Description · Form · File No. · Exhibit · Filing Date | ||||||||||
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 10-Q | 001-40236 | 3.1 | August 8, 2024 | |||||
| 3.2 | Amended and Restated Bylaws of the Registrant. | 8-K | 001-40236 | 3.2 | March 30, 2021 | |||||
| 4.1 | Amended and Restated Investors’ Rights Agreement by and among the Registrant and certain of its stockholders, dated December 3, 2020. | S-1 | 333-253923 | 4.1 | March 5, 2021 | |||||
| 4.2 | Specimen common stock certificate of the Registrant. | S-1 | 333-253923 | 4.2 | March 5, 2021 | |||||
| 4.3 | Description of Securities. | 10-K | 001-40236 | 4.3 | February 24, 2022 | |||||
| 4.4 | | Form of Indenture | | S-3ASR | | 333-279299 | | 4.4 | | May 10, 2024 |
| | | | | | | | | | | |
| 10.1˄ | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. | S-1 | 333-253923 | 10.1 | March 5, 2021 | |||||
| 10.2˄ | 2017 Equity Incentive Plan, as amended, and forms of agreement thereunder. | S-1 | 333-253923 | 10.2 | March 5, 2021 | |||||
| 10.3˄ | 2021 Equity Incentive Plan and forms of agreements thereunder. | S-1 | 333-253923 | 10.3 | March 5, 2021 | |||||
| 10.4˄ | 2021 Employee Stock Purchase Plan and forms of agreements thereunder. | S-1 | 333-253923 | 10.4 | March 5, 2021 | |||||
| | | | | | | | | | | |
| 10.5˄ | | 2021 Employee Stock Purchase Plan, as amended, and forms of agreement thereunder. | | 10-K | | 001-40236 | | 10.5 | | February 23, 2023 |
| 10.6˄ | | 2024 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements. | | 8-K | | 001-40236 | | 10.1 | | August 12, 2024 |
| | | | | | | | | | | |
| 10.7˄ | Offer Letter between the Registrant and Kevin Koch, Ph.D. | S-1 | 333-253923 | 10.5 | March 5, 2021 | |||||
| 10.8˄ | Offer Letter between the Registrant and Alan Russell, Ph.D. | S-1 | 333-253923 | 10.6 | March 5, 2021 | |||||
| 10.9˄ | Offer Letter between the Registrant and R. Michael Carruthers. | S-1 | 333-253923 | 10.8 | March 5, 2021 | |||||
| 10.10˄ | Offer Letter between the Registrant and Behrad Derakhshan, Ph.D. | S-1 | 333-253923 | 10.9 | March 5, 2021 | |||||
| 10.11˄ | Offer Letter between the Registrant and John Moore. | S-1 | 333-253923 | 10.10 | March 5, 2021 | |||||
| 10.12˄ | Offer Letter between the Registrant and Joanne Donovan, M.D., Ph.D. | 10-Q | 001-40236 | 10.1 | May 13, 2021 | |||||
| | | | | | | | | | | |
| 10.13˄ | | Offer Letter between the Registrant and Marc Semigran, M.D. | | 10-K | | 001-40236 | | 10.12 | | February 23, 2023 |
| | | | | | | | | | | |
| 10.14˄ | Executive Incentive Compensation Plan. | S-1 | 333-253923 | 10.11 | March 5, 2021 | |||||
| 10.15˄ | Executive Change in Control and Severance Plan. | S-1 | 333-253923 | 10.12 | March 5, 2021 | |||||
| 10.16Ù | Amended and Restated Outside Director Compensation Policy. | 10-Q | 001-40236 | 10.1 | May 11, 2023 | |||||
| 10.17Ù | | Form of Restricted Stock Unit Agreement. | | 10-Q | | 001-40236 | | 10.2 | | May 11, 2023 |
| | | | | | | | | | | |
| 10.18˄+ | | Stock Option Agreement between the Registrant and Dr. Alan Russell, dated as of September 19, 2017. | | S-8 | | 333-283051 | | 10.2 | | November 7, 2024 |
| | | | | | | | | | | |
| 10.19 | | Sales Agreement, dated May 10, 2024, by and between the Registrant and Leerink Partner LLC. | | S-3 | | 333-279299 | | 1.2 | | May 10, 2024 |
| | | | | | | | | | | |
| 10.20˄ | | Offer Letter between the Registrant and Robert Blaustein, M.D., Ph.D. | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 19.1 | | Insider Trading Policy | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 23.1 | | Consent of Independent Registered Public Accounting Firm. | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 31.1 | | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 31.2 | | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 32.1* | | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 97.1 | | Compensation Recovery Policy | | 10-K | | 001-40236 | | 97.1 | | February 22, 2024 |
| | | | | | | | | | | |
| 101.INS | | XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | Filed herewith | | | | | | |
| | | | | | | | | | | |
| 104 | | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | | Filed herewith | | | | | | |
| | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ù | Indicates management contract or compensatory plan. |
|---|
| + | Portions of this exhibit have been redacted in compliance with Regulation S-K Ite 601(a)(6). |
|---|
| * | The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.